US Food and Drug Administration Commissioner Robert Califf has emphasized the key public health paradox that in an era of unprecedented biomedical innovation, the country still faces an incredibly high chronic disease and early mortality burden.
Key Takeaways
-
A NASEM committee is researching whether drug development incentives and investments are aligned with unmet needs and disease burden.
-
The upcoming report could impact FDA rare disease and other incentives, as well as allow industry to seek more incentives for development in common diseases
“It is a conundrum,” Califf said during the 7 October meeting of the FDA’s Science Board. “We are leading the world. Everywhere I go, people are in awe of the innovation in the US. But we are continuing to lose ground compared to other high-income countries in our health status
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?